ME02189B - Farmaceutski dozni oblici sa kontrolisanim oslobađanjem - Google Patents
Farmaceutski dozni oblici sa kontrolisanim oslobađanjemInfo
- Publication number
- ME02189B ME02189B MEP-2015-116A MEP2015116A ME02189B ME 02189 B ME02189 B ME 02189B ME P2015116 A MEP2015116 A ME P2015116A ME 02189 B ME02189 B ME 02189B
- Authority
- ME
- Montenegro
- Prior art keywords
- pharmaceutical dosage
- sustained
- matrix formulation
- dosage forms
- controlled release
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title claims 2
- 238000013270 controlled release Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 claims 6
- 238000009472 formulation Methods 0.000 claims 4
- 239000011159 matrix material Substances 0.000 claims 4
- 238000013268 sustained release Methods 0.000 claims 4
- 239000012730 sustained-release form Substances 0.000 claims 4
- 239000013543 active substance Substances 0.000 claims 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 2
- 238000013265 extended release Methods 0.000 claims 1
- 238000000518 rheometry Methods 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161467824P | 2011-03-25 | 2011-03-25 | |
| EP20120717468 EP2688556B1 (en) | 2011-03-25 | 2012-03-22 | Controlled release pharmaceutical dosage forms |
| PCT/IB2012/000595 WO2012131463A2 (en) | 2011-03-25 | 2012-03-22 | Controlled release pharmaceutical dosage forms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02189B true ME02189B (me) | 2016-02-20 |
Family
ID=46018006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2015-116A ME02189B (me) | 2011-03-25 | 2012-03-22 | Farmaceutski dozni oblici sa kontrolisanim oslobađanjem |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20140056979A1 (enExample) |
| EP (1) | EP2688556B1 (enExample) |
| JP (1) | JP5964940B2 (enExample) |
| KR (1) | KR101619579B1 (enExample) |
| CN (1) | CN103547259A (enExample) |
| AU (1) | AU2012235878B2 (enExample) |
| BR (1) | BR112013024585A8 (enExample) |
| CA (1) | CA2831218C (enExample) |
| CY (1) | CY1116579T1 (enExample) |
| DK (1) | DK2688556T3 (enExample) |
| ES (1) | ES2544735T3 (enExample) |
| HR (1) | HRP20150835T1 (enExample) |
| HU (1) | HUE026981T2 (enExample) |
| IL (1) | IL228441B (enExample) |
| ME (1) | ME02189B (enExample) |
| MX (1) | MX350875B (enExample) |
| PH (1) | PH12013501994A1 (enExample) |
| PL (1) | PL2688556T3 (enExample) |
| PT (1) | PT2688556E (enExample) |
| RS (1) | RS54152B1 (enExample) |
| SI (1) | SI2688556T1 (enExample) |
| SM (1) | SMT201500209B (enExample) |
| WO (1) | WO2012131463A2 (enExample) |
| ZA (1) | ZA201307862B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
| ES2374717T3 (es) | 1999-10-29 | 2012-02-21 | Euro-Celtique S.A. | Formulaciones de hidrocodona de liberación controlada. |
| JP2004512354A (ja) | 2000-10-30 | 2004-04-22 | ユーロ−セルティーク，エス．エイ． | ヒドロコドン放出制御製剤 |
| EP1429744A1 (en) | 2001-09-21 | 2004-06-23 | Egalet A/S | Morphine polymer release system |
| WO2003024429A1 (en) | 2001-09-21 | 2003-03-27 | Egalet A/S | Polymer release system |
| ATE495732T1 (de) | 2003-03-26 | 2011-02-15 | Egalet As | Morphin-system mit kontrollierter freisetzung |
| EP2155167A2 (en) | 2007-06-04 | 2010-02-24 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
| EP2393484A1 (en) | 2009-02-06 | 2011-12-14 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
| EP2445487A2 (en) | 2009-06-24 | 2012-05-02 | Egalet Ltd. | Controlled release formulations |
| SG191288A1 (en) | 2010-12-22 | 2013-07-31 | Purdue Pharma Lp | Encased tamper resistant controlled release dosage forms |
| PH12013501345A1 (en) | 2010-12-23 | 2022-10-24 | Purdue Pharma Lp | Tamper resistant solid oral dosage forms |
| CA2868413C (en) | 2012-04-17 | 2021-07-20 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
| HK1210599A1 (en) | 2012-07-06 | 2016-04-29 | Egalet Ltd. | Abuse deterrent pharmaceutical compositions for controlled release |
| JP6208261B2 (ja) | 2013-02-05 | 2017-10-04 | パーデュー、ファーマ、リミテッド、パートナーシップＰｕｒｄｕｅ Ｐｈａｒｍａ Ｌ．Ｐ． | タンパリング抵抗性医薬製剤 |
| US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
| AU2014306759B2 (en) | 2013-08-12 | 2018-04-26 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| ES2809458T3 (es) | 2014-07-17 | 2021-03-04 | Pharmaceutical Manufacturing Res Services Inc | Forma de dosificación llena de líquido, disuasoria del abuso y de liberación inmediata |
| US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
| US9849124B2 (en) | 2014-10-17 | 2017-12-26 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
| WO2016064873A1 (en) | 2014-10-20 | 2016-04-28 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| US9839212B2 (en) | 2015-04-16 | 2017-12-12 | Bio-Lab, Inc. | Multicomponent and multilayer compacted tablets |
| WO2019006404A1 (en) | 2017-06-30 | 2019-01-03 | Purdue Pharma L.P. | METHOD OF TREATMENT AND DOSAGE FORMS |
| US11911510B2 (en) | 2017-08-31 | 2024-02-27 | Purdue Pharma L.P | Pharmaceutical dosage forms |
| EP3727384A4 (en) | 2017-12-20 | 2021-11-03 | Purdue Pharma L.P. | ABUSE-DISSUASIVE MORPHINE SULPHATE FORMES |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR950007907B1 (ko) * | 1992-09-01 | 1995-07-21 | 동국제약 주식회사 | 치주질환 치료용 막형 국소약물송달제제 |
| US5567439A (en) * | 1994-06-14 | 1996-10-22 | Fuisz Technologies Ltd. | Delivery of controlled-release systems(s) |
| US5634702A (en) | 1995-09-27 | 1997-06-03 | Fistonich; Juraj | Hands free waste container having a closed cover that automatically opens when the container is moved outside its cabinet enclosure |
| DE60123384T2 (de) * | 2000-02-04 | 2007-08-02 | DepoMed, Inc., Menlo Park | Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert |
| JP2004512354A (ja) * | 2000-10-30 | 2004-04-22 | ユーロ−セルティーク，エス．エイ． | ヒドロコドン放出制御製剤 |
| CA2572491A1 (en) * | 2004-07-01 | 2006-01-12 | Gruenenthal Gmbh | Oral dosage form safeguarded against abuse |
| US7434308B2 (en) * | 2004-09-02 | 2008-10-14 | International Business Machines Corporation | Cooling of substrate using interposer channels |
| JP2008536928A (ja) * | 2005-04-19 | 2008-09-11 | アルザ・コーポレーシヨン | トラマドール及び、ガバペンチンを含んでなる物質、の組み合わせ物 |
| WO2007133151A1 (en) * | 2006-05-17 | 2007-11-22 | Sandvik Intellectual Property Ab | A rock-drilling tool, a drill rod and coupling sleeve |
| SA07280459B1 (ar) * | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
| WO2009012122A1 (en) * | 2007-07-13 | 2009-01-22 | Marvell World Trade Ltd. | Method for shallow trench isolation |
| AU2009223061B2 (en) * | 2008-03-11 | 2014-10-09 | Depomed Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
| CN101933907A (zh) * | 2009-06-30 | 2011-01-05 | 北京天衡药物研究院 | 新型骨架缓释片及其制备方法 |
-
2012
- 2012-03-22 US US14/004,857 patent/US20140056979A1/en not_active Abandoned
- 2012-03-22 WO PCT/IB2012/000595 patent/WO2012131463A2/en not_active Ceased
- 2012-03-22 BR BR112013024585A patent/BR112013024585A8/pt not_active Application Discontinuation
- 2012-03-22 DK DK12717468.8T patent/DK2688556T3/en active
- 2012-03-22 EP EP20120717468 patent/EP2688556B1/en active Active
- 2012-03-22 HU HUE12717468A patent/HUE026981T2/en unknown
- 2012-03-22 CA CA2831218A patent/CA2831218C/en active Active
- 2012-03-22 RS RS20150515A patent/RS54152B1/sr unknown
- 2012-03-22 CN CN201280020303.9A patent/CN103547259A/zh active Pending
- 2012-03-22 ME MEP-2015-116A patent/ME02189B/me unknown
- 2012-03-22 HR HRP20150835TT patent/HRP20150835T1/hr unknown
- 2012-03-22 PT PT127174688T patent/PT2688556E/pt unknown
- 2012-03-22 MX MX2013010987A patent/MX350875B/es active IP Right Grant
- 2012-03-22 PL PL12717468T patent/PL2688556T3/pl unknown
- 2012-03-22 SI SI201230275T patent/SI2688556T1/sl unknown
- 2012-03-22 KR KR1020137027839A patent/KR101619579B1/ko active Active
- 2012-03-22 ES ES12717468.8T patent/ES2544735T3/es active Active
- 2012-03-22 JP JP2014500486A patent/JP5964940B2/ja active Active
- 2012-03-22 PH PH1/2013/501994A patent/PH12013501994A1/en unknown
- 2012-03-22 AU AU2012235878A patent/AU2012235878B2/en active Active
-
2013
- 2013-09-15 IL IL228441A patent/IL228441B/en active IP Right Grant
- 2013-10-22 ZA ZA2013/07862A patent/ZA201307862B/en unknown
-
2015
- 2015-08-03 CY CY20151100677T patent/CY1116579T1/el unknown
- 2015-09-09 SM SM201500209T patent/SMT201500209B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2688556B1 (en) | 2015-05-06 |
| WO2012131463A3 (en) | 2012-11-29 |
| HUE026981T2 (en) | 2016-08-29 |
| CA2831218A1 (en) | 2012-10-04 |
| US20140056979A1 (en) | 2014-02-27 |
| ES2544735T3 (es) | 2015-09-03 |
| EP2688556A2 (en) | 2014-01-29 |
| MX2013010987A (es) | 2014-10-13 |
| NZ616600A (en) | 2015-07-31 |
| WO2012131463A2 (en) | 2012-10-04 |
| AU2012235878B2 (en) | 2015-10-15 |
| KR101619579B1 (ko) | 2016-05-10 |
| PH12013501994A1 (en) | 2013-12-02 |
| PL2688556T3 (pl) | 2015-10-30 |
| IL228441B (en) | 2019-05-30 |
| SI2688556T1 (sl) | 2015-09-30 |
| RS54152B1 (sr) | 2015-12-31 |
| CY1116579T1 (el) | 2017-03-15 |
| MX350875B (es) | 2017-09-19 |
| IL228441A0 (en) | 2013-12-31 |
| CA2831218C (en) | 2017-01-17 |
| JP5964940B2 (ja) | 2016-08-03 |
| HRP20150835T1 (hr) | 2015-09-11 |
| JP2014510094A (ja) | 2014-04-24 |
| DK2688556T3 (en) | 2015-08-03 |
| KR20130135973A (ko) | 2013-12-11 |
| ZA201307862B (en) | 2014-06-25 |
| CN103547259A (zh) | 2014-01-29 |
| AU2012235878A1 (en) | 2013-05-02 |
| SMT201500209B (it) | 2015-10-30 |
| PT2688556E (pt) | 2015-09-11 |
| BR112013024585A8 (pt) | 2018-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02189B (me) | Farmaceutski dozni oblici sa kontrolisanim oslobađanjem | |
| AR081760A1 (es) | Una composicion farmaceutica para administracion oral que comprende acido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoico, un metodo para producir la misma, una tableta y una forma unitaria de dosificacion oral que la comprende y el uso de la misma para la fabricacion de un medicamento | |
| ES2478264T3 (es) | Glicerosomas y uso de estos en preparaciones farmacéuticas y cosméticas para aplicación tópica | |
| BRPI0809667A2 (pt) | Composto, medicamento e composição farmacêutica que o contém e uso do composto | |
| ECSP14013168A (es) | Tableta a prueba de manipulación que proporciona liberación de fármaco inmediato | |
| EA201001244A1 (ru) | Система доставки лекарственного средства со стабилизирующим эффектом | |
| JP2010285439A5 (enExample) | ||
| WO2009074351A3 (en) | Solid forms of tenofovir disoproxil | |
| CL2011002968A1 (es) | Forma de dosificacion de extrusion por fusion caliente de un ingrediente activo (a) incluido en una matriz que comprende un polimero (c), que el nucleo presenta una orientacion morfologica ortogonal respecto a la direccion longitudinal de extension de la forma de dosificacion; y su procedimiento de preparacion. | |
| CY1115652T1 (el) | Μορφη δοσολογιας που περιεχει δυο δραστικα φαρμακευτικα συστατικα μειγματος σε διαφορετικες φυσικες μορφες | |
| CU20080052A7 (es) | Formas de presentación farmacéutica sólidas de administración oral con liberación rápida de principio activo | |
| EP2475427A4 (en) | ACTRIIB ANTAGONISTS, THEIR DOSAGE AND APPLICATIONS THEREOF | |
| AR072950A1 (es) | Uso de dronedarona para la preparacion de un medicamento para uso en la prevencion de la hospitalizacion cardiovascular o de la mortalidad, composicion farmaceutica, articulo de fabricacion y envase | |
| BR112012024139A2 (pt) | formulações farmacêuticas de camada dupla contendo agonistas e antagonistas de opióide. | |
| BRPI0814666A2 (pt) | composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida | |
| EP4209513A4 (en) | BISPECIFIC ANTI-VEGF-ANTI-PD-L1 ANTIBODY, PHARMACEUTICAL COMPOSITION THEREOF AND RELATED USES | |
| TR200806298A2 (tr) | Farmasötik formülasyon | |
| EA201690679A1 (ru) | Стабильная фармацевтическая композиция, содержащая амлодипин и валсартан | |
| NO20082047L (no) | Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme | |
| JP2015514739A5 (enExample) | ||
| ECSP10010683A (es) | Una formulacion farmacéutica sólida | |
| IT1401284B1 (it) | Nuove formulazioni farmaceutiche idonee per la somministrazione orale di esomeprazolo magnesio diidrato, in forma di compresse mups (multi unit pellets system). | |
| WO2011130834A8 (en) | Non-intravenous dosage form comprising solid formulation of liquid biologically active agent and uses thereof | |
| BR112014004753A2 (pt) | formulação de liberação de multicamadas | |
| MA50394A (fr) | Formulations pharmaceutiques comprenant un agoniste de récepteur d'opioïde en tant que substances actives, leurs procédés de fabrication et leurs utilisations thérapeutiques |